Overview

Bosentan and Pulmonary Endothelial Function

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
6 months therapy of Bosentan, an endothelin antagonist, will lead to improvement in pulmonary microvascular endothelial function.
Phase:
N/A
Details
Lead Sponsor:
Prof David S Celermajer
Treatments:
Bosentan